NICE Nod To Lucentis For ME Raises Unlicensed Comparator Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.